Literature DB >> 12887134

Differential induction of protein kinase C isoforms at the cardiac hypertrophy stage and congestive heart failure stage in Dahl salt-sensitive rats.

Yuichi Koide1, Kouichi Tamura, Atsushi Suzuki, Kouichi Kitamura, Keiko Yokoyama, Tatsuo Hashimoto, Nobuhito Hirawa, Minoru Kihara, Shigeo Ohno, Satoshi Umemura.   

Abstract

Several protein kinase C (PKC) isoforms may play important roles in cellular signaling pathways. Recent reports have suggested that PKC plays critical isoform-specific roles in the development of cardiac hypertrophy and heart failure. The purpose of the present study was to examine the expression profiles of PKC isoforms in models of cardiac hypertrophy and heart failure. We examined the cardiac expression of individual PKC isoforms at the cardiac hypertrophy stage and the heart failure stage in Dahl salt-sensitive rats by Western blot analysis. The levels of all PKC isoforms increased at the cardiac hypertrophy stage and the heart failure stage, but the pattern of increase differed among PKC isoforms at the heart failure stage. The expressions of PKCalpha, beta, and delta increased at the cardiac hypertrophy stage and remained elevated at the heart failure stage. On the other hand, the expression of PKCepsilon and atypical PKCs (aPKCs) increased at the cardiac hypertrophy stage, but this increase tended to decline at the congestive heart failure stage. These results suggest that there are two groups of PKC isoforms. Several reports have shown that PKCalpha, beta, and delta are involved in the development of cardiac hypertrophy and heart failure, and that PKCepsilon plays a role in the physiological hypertrophic responses and cardioprotective actions. These facts suggest that all PKC isoforms (PKCalpha, beta, delta, epsilon, and aPKCs) expressed in the heart may have similar functions at the cardiac hypertrophy stage, but that two groups of PKC isoforms (PKCalpha, beta, delta, and PKCepsilon, aPKCs) have different functions at the congestive heart failure stage.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12887134     DOI: 10.1291/hypres.26.421

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  18 in total

Review 1.  βIIPKC and εPKC isozymes as potential pharmacological targets in cardiac hypertrophy and heart failure.

Authors:  Julio Cesar Batista Ferreira; Patricia Chakur Brum; Daria Mochly-Rosen
Journal:  J Mol Cell Cardiol       Date:  2010-10-28       Impact factor: 5.000

2.  Doxercalciferol, a pro-hormone of vitamin D, prevents the development of cardiac hypertrophy in rats.

Authors:  Jun H Choi; Qingen Ke; Soochan Bae; Ji Yoo Lee; Yu Jin Kim; Ui Kyoung Kim; Cynthia Arbeeny; Ravi Thadhani; Peter M Kang
Journal:  J Card Fail       Date:  2011-09-09       Impact factor: 5.712

3.  Dose-dependent cardiac effect of oestrogen replacement in mice post-myocardial infarction.

Authors:  Enbo Zhan; Thomas Keimig; Jiang Xu; Edward Peterson; Jennifer Ding; Fangfei Wang; Xiao-Ping Yang
Journal:  Exp Physiol       Date:  2008-05-16       Impact factor: 2.969

4.  Maladaptation of calcium homoeostasis in aging cardiac myocytes.

Authors:  Paul Goldspink; Stuart Ruch; Tamara Los; Peter Buttrick; Jesús García
Journal:  Pflugers Arch       Date:  2008-01-03       Impact factor: 3.657

5.  Phosphoinositide 3-kinase Akt signaling pathway interacts with protein kinase Cbeta2 in the regulation of physiologic developmental hypertrophy and heart function.

Authors:  Debra L Rigor; Natalya Bodyak; Soochan Bae; Jun H Choi; Li Zhang; Dmitry Ter-Ovanesyan; Zhiheng He; Julie R McMullen; Tetsuo Shioi; Seigo Izumo; George L King; Peter M Kang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-01-02       Impact factor: 4.733

6.  PKCβII modulation of myocyte contractile performance.

Authors:  Hyosook Hwang; Dustin A Robinson; Tamara K Stevenson; Helen C Wu; Sarah E Kampert; Francis D Pagani; D Brad Dyke; Jody L Martin; Sakthival Sadayappan; Sharlene M Day; Margaret V Westfall
Journal:  J Mol Cell Cardiol       Date:  2012-05-14       Impact factor: 5.000

7.  PKCepsilon increases phosphorylation of the cardiac myosin binding protein C at serine 302 both in vitro and in vivo.

Authors:  Lei Xiao; Qiong Zhao; Yanmei Du; Chao Yuan; R John Solaro; Peter M Buttrick
Journal:  Biochemistry       Date:  2007-05-16       Impact factor: 3.162

Review 8.  Protein kinase C, an elusive therapeutic target?

Authors:  Daria Mochly-Rosen; Kanad Das; Kevin V Grimes
Journal:  Nat Rev Drug Discov       Date:  2012-12       Impact factor: 84.694

9.  Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure.

Authors:  Michael Hambleton; Harvey Hahn; Sven T Pleger; Matthew C Kuhn; Raisa Klevitsky; Andrew N Carr; Thomas F Kimball; Timothy E Hewett; Gerald W Dorn; Walter J Koch; Jeffery D Molkentin
Journal:  Circulation       Date:  2006-07-31       Impact factor: 29.690

10.  Upregulation of COX-2 and PGE2 Induced by TNF-α Mediated Through TNFR1/MitoROS/PKCα/P38 MAPK, JNK1/2/FoxO1 Cascade in Human Cardiac Fibroblasts.

Authors:  Chuen-Mao Yang; Chien-Chung Yang; Li-Der Hsiao; Chia-Ying Yu; Hui-Ching Tseng; Chih-Kai Hsu; Jiro Hasegawa Situmorang
Journal:  J Inflamm Res       Date:  2021-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.